, Les émissions de CO2 liées à la consommation de carburants sont moins taxées que dans la plupart des autres pays

, Graphique 22.1. Les femmes ont généralement une espérance de vie plus longue que les hommes, mais leur espérance de vie en bonne santé est équivalente

, UN AUTRE REGARD SUR LE CHANGEMENT, Le mouvement de l'être, pp.143-154, 2011.

P. Nowell and D. Hungerford, Commentary on and reprint of Nowell PC, Hungerford DA, A minute chromosome in human chronic granulocytic leukemia, in Science (1960) 132:1497, Hematology, vol.132, pp.513-515, 2000.

A. De-klein, A. G. Van-kessel, G. Grosveld, C. R. Bartram, A. Hagemeijer et al., Acellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia, Nature, vol.300, pp.765-772, 1982.

S. Thijsen, G. J. Schuurhuis, J. W. Van-oostveen, and G. J. Ossenkoppele, Chronic myeloid leukemia from basics to bedside, Leukemia, vol.13, issue.11, pp.1646-1674, 1999.

T. Leguay and F. Mahon, Leucémie myéloïde chronique, EMC - Hématologie, vol.2, issue.3, pp.187-205, 2005.

M. W. Deininger, J. M. Goldman, and J. V. Melo, The molecular biology of chronic myeloid leukemia, Blood, vol.96, issue.10, pp.3343-3356, 2000.

A. Oda, Y. Miyakawa, B. J. Druker, A. Ishida, K. Ozaki et al., Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin, Blood, vol.88, issue.11, pp.4304-4313, 1996.

T. Skorski, A. Bellacosa, M. Nieborowska-skorska, M. Majewski, R. Martinez et al., Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway, The EMBO Journal, vol.16, issue.20, pp.6151-6161, 1997.

R. P. De-groot, J. A. Raaijmakers, J. Lammers, R. Jove, and L. Koenderman, STAT5 Activation by BCR-Abl Contributes to Transformation of K562 Leukemia Cells, Blood, vol.94, issue.3, pp.1108-1112, 1999.

Z. Dai, R. C. Quackenbush, K. D. Courtney, M. Grove, D. Cortez et al., Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway, Genes & Development, vol.12, issue.10, pp.1415-1424, 1998.

F. Mahon and G. Etienne, Deep Molecular Response in Chronic Myeloid Leukemia: The New Goal of Therapy?, Clinical Cancer Research, vol.20, issue.2, pp.310-322, 2013.

S. G. O'brien, F. Guilhot, R. A. Larson, I. Gathmann, M. Baccarani et al., Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia, New England Journal of Medicine, vol.348, issue.11, pp.994-1004, 2003.

B. J. Druker, F. Guilhot, S. G. O'brien, I. Gathmann, H. Kantarjian et al., Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia, New England Journal of Medicine, vol.355, issue.23, pp.2408-2417, 2006.

M. , S. C. Letvak, L. Larson, and R. A. , Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia, N Engl J Med, vol.355, pp.2408-2425, 2006.

A. Hochhaus, S. G. O'brien, F. Guilhot, B. J. Druker, S. Branford et al., Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia, Leukemia, vol.23, issue.6, pp.1054-1061, 2009.

A. Hochhaus, R. A. Larson, F. Guilhot, J. P. Radich, S. Branford et al., Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia, New England Journal of Medicine, vol.376, issue.10, pp.917-927, 2017.

L. Roy, J. Guilhot, T. Krahnke, A. Guerci-bresler, B. J. Druker et al., Survival advantage from imatinib compared with the combination interferon-? plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials, Blood, vol.108, issue.5, pp.1478-1484, 2006.

H. De-lavallade, J. F. Apperley, J. S. Khorashad, D. Milojkovic, A. G. Reid et al., Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis, Journal of Clinical Oncology, vol.26, issue.20, pp.3358-3363, 2008.

L. Kalmanti, S. Saussele, M. Lauseker, M. C. Müller, C. T. Dietz et al., Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV, Leukemia, vol.29, issue.5, pp.1123-1132, 2015.

J. E. Cortes, G. Saglio, H. M. Kantarjian, M. Baccarani, J. Mayer et al., Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial, Journal of Clinical Oncology, vol.34, issue.20, pp.2333-2340, 2016.

A. Hochhaus, G. Saglio, T. P. Hughes, R. A. Larson, D. Kim et al., Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial, Leukemia, vol.30, issue.5, pp.1044-1054, 2016.

H. D. Dalal, H. M. Menssen, and . Kantarjian, Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial, Leukemia, vol.30, pp.1044-1054, 2016.

J. E. Cortes, C. Gambacorti-passerini, M. W. Deininger, M. J. Mauro, C. Chuah et al., Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial, Journal of Clinical Oncology, vol.36, issue.3, pp.231-237, 2018.

J. E. Cortes, C. Gambacorti-passerini, M. W. Deininger, M. J. Mauro, C. Chuah et al., Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial, Journal of Clinical Oncology, vol.36, issue.3, pp.231-237, 2018.

J. E. Cortes, D. Kim, J. Pinilla-ibarz, P. Le-coutre, R. Paquette et al., A Phase 2 Trial of Ponatinib in Philadelphia Chromosome?Positive Leukemias, New England Journal of Medicine, vol.369, issue.19, pp.1783-1796, 2013.

J. H. Lipton, C. Chuah, A. Guerci-bresler, G. Rosti, D. Simpson et al., Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial, The Lancet Oncology, vol.17, issue.5, pp.612-621, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01812697

T. P. Hughes, A. Hochhaus, S. Branford, M. C. Müller, J. S. Kaeda et al., Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS), Blood, vol.116, issue.19, pp.3758-3765, 2010.

D. Marin, C. Hedgley, R. E. Clark, J. Apperley, L. Foroni et al., Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib, Blood, vol.120, issue.2, pp.291-294, 2012.

B. Hanfstein, M. C. Müller, R. Hehlmann, P. Erben, M. Lauseker et al., Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML), Leukemia, vol.26, issue.9, pp.2096-2102, 2012.

R. A. Larson, B. J. Druker, F. Guilhot, S. G. O'brien, G. J. Riviere et al., Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study, Blood, vol.111, issue.8, pp.4022-4028, 2008.

S. Dulucq, S. Bouchet, B. Turcq, E. Lippert, G. Etienne et al., Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia, Blood, vol.112, issue.5, pp.2024-2027, 2008.

D. L. White, V. A. Saunders, A. Frede, P. Dang, S. Zrim et al., The Functional Activity of the OCT-1 Protein Is Predictive of Molecular Response and Survival in CP-CML Patients Treated with Imatinib: A 5 Year Update of the TIDEL Trial., Blood, vol.114, issue.22, pp.507-507, 2009.

A. R. Ibrahim, L. Eliasson, and J. F. Apperley, Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011;117(14):3733?3736., Blood, vol.120, issue.24, pp.4903-4903, 2012.

J. Cortes, S. O'brien, and H. Kantarjian, Discontinuation of imatinib therapy after achieving a molecular response, Blood, vol.104, issue.7, pp.2204-2205, 2004.

P. Rousselot, F. Huguet, D. Rea, L. Legros, J. M. Cayuela et al., Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years, Blood, vol.109, issue.1, pp.58-60, 2006.

F. Mahon, D. Réa, J. Guilhot, F. Guilhot, F. Huguet et al., Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial, The Lancet Oncology, vol.11, issue.11, pp.1029-1035, 2010.

G. Etienne, J. Guilhot, D. Rea, F. Rigal-huguet, F. Nicolini et al., Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia, Journal of Clinical Oncology, vol.35, issue.3, pp.298-305, 2017.

P. Rousselot, A. Charbonnier, P. Cony-makhoul, P. Agape, F. E. Nicolini et al., Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease, Journal of Clinical Oncology, vol.32, issue.5, pp.424-430, 2014.

D. M. Ross, S. Branford, J. F. Seymour, A. P. Schwarer, C. Arthur et al., Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study, Blood, vol.122, issue.4, pp.515-522, 2013.

S. Lee, S. Y. Choi, H. Song, S. Kim, M. Choi et al., Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study, Haematologica, vol.101, issue.6, pp.717-723, 2016.

J. Richter, F. X. Mahon, J. Guilhot, H. Hjorth-hansen, A. Almedia et al., Stopping tyrosine kinaseinhibitors in a very large cohort of European chronicmyeloid leukemia patients: Results of the EURO-SKItrial. 21st EHA Congress, Haematologica, vol.101, p.145, 2016.

S. Saussele, J. Richter, J. Guilhot, F. X. Gruber, H. Hjorth-hansen et al., Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial, The Lancet Oncology, vol.19, issue.6, pp.747-757, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01859932

D. Rea, F. E. Nicolini, M. Tulliez, F. Guilhot, J. Guilhot et al., Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study, Blood, vol.129, issue.7, pp.846-854, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02050833

. Hughest, C. Boquimpani, N. Takahashi, N. Benyamini, N. Clementino et al.,

T. P. Hughes, C. M. Boquimpani, N. Takahashi, N. Benyamini, N. C. Clementino et al., Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop, Blood, vol.128, issue.22, pp.792-792, 2016.

F. Mahon, C. Boquimpani, N. Takahashi, N. Benyamini, N. C. Clementino et al., PF411 ENESTOP 192-WK RESULTS: DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT-FREE REMISSION (TFR) FOLLOWING SECOND-LINE (2L) NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML), HemaSphere, vol.3, issue.S1, p.158, 2019.

T. Hughes, Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study Ann Intern Med, vol.168, pp.461-470, 2018.

D. M. Ross, T. Masszi, M. T. Gómez-casares, A. Hellmann, J. Stentoft et al., Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study, Journal of Cancer Research and Clinical Oncology, vol.144, issue.5, pp.945-954, 2018.

N. Takahashi, K. Nishiwaki, C. Nakaseko, N. Aotsuka, K. Sano et al., Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan, Haematologica, vol.103, issue.11, pp.1835-1842, 2018.

N. Kadowaki, T. Kawaguchi, J. Kuroda, H. Nakamae, I. Matsumura et al., Discontinuation of Nilotinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Deep Molecular Responses for at Least 2 Years: A Multicenter Phase 2 Stop Nilotinib (Nilst) Trial, Blood, vol.128, issue.22, pp.790-790, 2016.

N. P. Shah, R. Paquette, and M. C. Müller, Treatment-free remission (TFR) in patients with chronic phase chronic myeloid leukemia (CML-CP) and in stable deep molecular response (DMR) to dasatinib -the DASFREE Study, Blood, vol.128, 2016.

T. Kumagai, C. Nakaseko, K. Nishiwaki, C. Yoshida, K. Ohashi et al., Discontinuation of Dasatinib after Deep Molecular Response for over 2 Years in Patients with Chronic Myelogenous Leukemia and the Unique Profiles of Lymphocyte Subsets for Successful Discontinuation: A Prospective, Multicenter Japanese Trial (D-STOP Trial), Blood, vol.128, issue.22, pp.791-791, 2016.

P. Rousselot, S. Boucher, G. Etienne, F. E. Nicolini, E. Chauzit et al., Pharmacokinetics of Dasatinib as a First Line Therapy In Newly Diagnosed CML Patients (OPTIM dasatinib trial): Correlation with Safety and Response., Blood, vol.116, issue.21, pp.3432-3432, 2010.

J. Imagawa, H. Tanaka, M. Okada, H. Nakamae, M. Hino et al., Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial, The Lancet Haematology, vol.2, issue.12, pp.e528-e535, 2015.

M. Okada, J. Imagawa, H. Tanaka, H. Nakamae, M. Hino et al., Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment, Clinical Lymphoma Myeloma and Leukemia, vol.18, issue.5, pp.353-360.e1, 2018.

R. E. Clark, F. Polydoros, J. F. Apperley, D. Milojkovic, K. Rothwell et al., De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial, The Lancet Haematology, vol.6, issue.7, pp.e375-e383, 2019.

H. Lavallade, W. Osborne, G. Campbell, L. Robinson, J. Ewing et al., Final results of the DESTINY study of de-escalation and stopping treatment in chronic myeloid leukemia, Haematologica, vol.809, 2018.

D. Dong-hwan-kim, L. Busque, D. L. Forrest, L. Savoie, I. Bence-bruckler et al., Second Attempt of TKI Discontinuation with Dasatinib for Treatment-Free Remission after Failing First Attempt with Imatinib: Treatment-Free Remission Accomplished By Dasatinib (TRAD), Trial Blood, vol.132, p.787, 2018.

L. Legros, F. E. Nicolini, G. Etienne, P. Rousselot, D. Rea et al., Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia, Cancer, vol.123, issue.22, pp.4403-4410, 2017.

A. Toubert, A. Turhan, A. Guerci-bresler, N. Dulphy, and D. Réa, Lymphocytes NK : un rôle majeur dans le contrôle immunologique de la leucémie myéloïde chronique, médecine/sciences, vol.34, issue.6-7, pp.540-546, 2018.

D. Rea, G. Henry, Z. Khaznadar, G. Etienne, F. Guilhot et al., Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study, Haematologica, vol.102, issue.8, pp.1368-1377, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02043232

A. Hughes, J. Clarson, C. Tang, L. Vidovic, D. L. White et al., CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors, Blood, vol.129, issue.9, pp.1166-1176, 2017.

F. Massaro, G. Colafigli, M. Molica, and M. Breccia, Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy, Expert Review of Hematology, vol.11, issue.4, pp.301-306, 2018.